WeVote
Log In

Bill

Bill

HB 263

Biological and neural data of individuals; certain disclosures, transfers, and use by a health and fitness app prohibited without express consent, Attorney General authorized to enforce, civil penalties provided

2026 Regular Session Introduced by Ben Robbins

Alabama requires companies to obtain explicit consumer consent before collecting or using biological and neural data, with Attorney General enforcement and civil penalties.

Reported Out of Committee Second House
#consumerprotection
0
WeVote Research Nonpartisan
Bill Summary · HB 263

Legislative bill overview

HB 263 requires covered entities to obtain express written consent from consumers before collecting, disclosing, transferring, or using their biological and neural data. The bill authorizes Alabama's Attorney General to enforce these requirements and establishes civil penalties for violations.

Why is this important

As biotechnology and neurotechnology advance, biological data (DNA, biometrics) and neural data (brain-computer interface information) are increasingly valuable to companies and researchers. Without clear protections, individuals could have sensitive personal information collected and used without their knowledge, raising privacy and autonomy concerns. This bill attempts to establish baseline consumer control over emerging data types that existing privacy laws may not adequately cover.

Potential points of contention

  • Definition scope: The bill's definitions of "biological data" and "neural data" may be too broad (capturing routine medical records) or too narrow (missing emerging biotechnologies), creating compliance confusion or loopholes
  • "Express consent" burden: Requiring explicit consent for every use could significantly slow medical research, public health initiatives, and clinical care that typically rely on less stringent consent mechanisms
  • Competitive disadvantage: Stricter Alabama requirements than neighboring states could push biotech companies and research institutions to relocate, potentially harming state economic development
  • Enforcement practicality: The Attorney General may lack resources to investigate and enforce against large national/international entities, making the law difficult to implement effectively
  • Exception clarity: The bill's carve-outs for legitimate uses (medical treatment, public health, law enforcement) are not detailed in the summary and could be subject to broad interpretation

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.